# OnCo record paper-giaccone-pembrolizumab-thymic-carcinoma-lancet-oncol-2018 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-giaccone-pembrolizumab-thymic-carcinoma-lancet-oncol-2018/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-giaccone-pembrolizumab-thymic-carcinoma-lancet-oncol-2018" ;
  schema:name "Pembrolizumab in patients with thymic carcinoma: a single-arm phase 2 study"@en ;
  schema:description "Immunotherapy shrank thymic carcinoma in about one patient in five after chemotherapy, but caused severe immune attacks on the heart and muscle more often than in other cancers, so it is used with care."@en ;
  schema:url <https://onco.cc/key-papers/paper-giaccone-pembrolizumab-thymic-carcinoma-lancet-oncol-2018/> ;
  schema:dateModified "2026-09-18"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S1470-2045(18)30062-7>, <https://pubmed.ncbi.nlm.nih.gov/29395863/> ;
  schema:sameAs <https://doi.org/10.1016/S1470-2045(18)30062-7> ;
  schema:datePublished "2018"^^xsd:gYear ;
  schema:author "Giaccone G, Kim C, Thompson J, et al." ;
  onco:cancers <https://onco.cc/cancers/thymic-carcinoma/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/> ;
  onco:journals <https://onco.cc/journals/lancet-oncology/> .